TRANSVAC-DS logo_200714.png

Work Packages

Work Package 1 | Coordination


Led by

European Vaccine Initiative

An effective management framework will be set up to ensure that all work packages progress towards their planned objectives within the predefined contractual requirements and time frames.


Work Package 2 | Gaps and needs analysis and context analysis of research infrastructure landscape

Led by


An in-depth assessment of existing needs and gaps in current vaccine development will be conducted, involving a large representation of external stakeholders from public, private and governmental/non-profit sectors. This analysis will conclude with identifying strengths, gaps, challenges and opportunities for the establishment of a vaccine R&D infrastructure as an efficient and effective means of addressing the existing needs that have been identified

Work Package 3 | Feasibility and option analysis – governance, finance and business models


Led by

European Vaccine Initiative

WP3 aims to ensure appropriate governance and financial management of the infrastructure and to design the infrastructure’s business model through five goals: (1) Develop a menu of possible alternative approaches (‘options’) for the overall design of a vaccine infrastructure, based on recommendations for the strategic positioning of vaccine R&D infrastructure (2) Prioritise a leading conceptual design based on a standard set of criteria, including impact, financial plausibility and supply and demand; (3) Define a clear governance structure for the EU vaccine R&D infrastructure; (4) Prepare a detailed five-year business plan for the future implementation of the vaccine R&D infrastructure; (5) Ensure operational integration with existing research infrastructures operating in the EU vaccine R&D space

Work Package 4 | Stakeholder engagement strategy


Led by

European Vaccine Initiative

The goal of WP4 is to identify and engage external stakeholders relevant for this design study. The specific objectives of this work package are to: (1) Update the registry of stakeholders that are key for a vaccine infrastructure; (2) Further develop a stakeholder engagement strategy that provides stakeholders with an opportunity to contribute to, support and influence the conceptual and technical design and planning of the infrastructure; (3) Raise overall awareness of the establishment of a vaccine R&D infrastructure by identifying the most effective communication channels, tools and measures.

Work Package 5 | Socio-economic impact analysis


Led by

 Helmholtz Centre for Infection Research (HZI)

The objective WP5 is to plan and subsequently assess the socioeconomic impact of the vaccine R&D infrastructure. This work package will thus have two main goals: (1) Develop a methodology to evaluate the socioeconomic impact of the infrastructure; (2) Conduct a socioeconomic impact assessment for a vaccine R&D infrastructure.


Work Package 6 | Communication and Dissemination

Led by

Flanders Vaccines

WP6 aims to develop and implement a comprehensive approach for communication and dissemination of the project results. The specific objectives of this work package are to: (1) Develop a comprehensive communication plan to promote the project and its results by providing targeted information to multiple audiences; (2) Prepare an exploitation and dissemination plan for sharing project results with potential users and for using the results for commercial purposes and policy making; (3) Implement corresponding strategies to ensure the appropriate protection of project results.

Work Package 7 | Ethics


Led by

Institut de Recerca I Tecnologica Agroalimentaries

The goal of this work package is to identify and address all relevant ethical issues that could arise from the activities conducted by a future permanent vaccine R&D infrastructure, and develop strategies for handling them. The specific objectives of this work package are to: (1) Identify all potential ethical issues that might arise during the preparation, implementation and operation of a vaccine infrastructure; (2) Ensure compliance with all applicable and relevant ethics requirements; (3) Encourage and promote alternative approaches with fewer ethical implications; (4) Develop guidance and recommendations for handling sensitive issues.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement N° 951668.

Apply for Vaccine R&D services and Training:


  • LinkedIn
  • Twitter

© 2021 European Vaccine Initiative. Designed by European Vaccine Initiative